Esperion Therapeutics Balance Sheet - Quarterly (NASDAQ:ESPR)

Add to My Stocks
$34.79 $0.87 (2.44%) ESPR stock closing price Mar 29, 2017 (Closing)

A thorough fundamental analysis involves using data from Esperion Therapeutics balance sheet, apart from other financial statements, to value the business. As in our Esperion Therapeutics stock analysis, analyzing a company also involves looking at the company's assets and liabilities as given in its balance sheet, which can be used to measure financial performance. A company releases its balance sheet every quarter along with its quarterly results. The Esperion Therapeutics balance sheet for 2016-Q4 shows cash on hand of $38.16M. The cash has decreased by $8.98M. View Esperion Therapeutics quarterly results to get the balance sheet details for the latest & last 40 quarters data..

show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Marketable Securities173.41M162.96M158.41M157.26M134.92M134.77M94.99M69.46M20.8M12.72M
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets1.99M3.36M1.91M2.58M2.13M3.24M0.93M1.71M0.92M1.61M
Esperion Therapeutics Total Current Assets
Property Plant & Equipment1.28M---1.16M---1.18M-
Accumulated Depreciation0.6M---0.35M---0.4M-
Esperion Therapeutics Net Property Plant & Equipment
Investment & Advances30.9M49.64M67.63M88.18M80.31M86.77M89.5M44.61M35.74M5.05M
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets----------
Esperion Therapeutics Total Assets
Notes Payable----------
Accounts Payable4.59M1.78M1.56M1.54M0.7M1.97M3.3M2.89M2.04M3.29M
Current Portion Long-Term Debt1.7M1.68M1.65M1.62M1.6M1.57M1.42M1.03M0.63M0.25M
Current Portion Capital Leases----------
Accrued Expenses9.28M4.69M4.41M2.82M3.31M3.27M2.29M3.01M2.81M2.07M
Income Taxes Payable----------
Other Current Liabilities----------
Esperion Therapeutics Total Current Liabilities
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt1.02M1.45M1.87M2.28M2.68M3.08M3.47M3.85M4.29M4.67M
Non-Current Capital Leases----------
Other Long-Term Liabilities----------
Esperion Therapeutics Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.01M
Capital Surplus457.95M454.37M450.66M446.52M441.94M437.54M433.79M430.34M238.03M145.18M
Retained Earnings-229.2M-200.24M-182.84M-168.8M-154.22M-141.1M-128.29M-115.9M-104.43M-94.98M
Treasury Stock----------
Other Liabilities-0.17M0.02M0.11M0.01M-0.48M0.01M-0.06M-0.03M-0.05M-
Esperion Therapeutics Shareholders Equity
Esperion Therapeutics Total Liabilities & Shareholders Equity
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Balance sheet for another ticker

Looking at Esperion Therapeutics historical stock prices and the current Esperion Therapeutics stock price can tell you how the stock price has moved, whereas the Esperion Therapeutics PE ratio chart shows if its shares are overpriced in comparison to peers. The important things to look for in a balance sheet are:
  • Assets: ESPR total assets, which was at $245.21M for 2016-Q4 is a balance sheet item representing value of what Esperion Therapeutics owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities: The total liabilities of Esperion Therapeutics for 2016-Q4 total to $16.61M. Liabilities for a company like Esperion Therapeutics include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.